Floatz logo

Galantamine Hydrobromide

Cognition Disorder

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

150 Active assets in the Cognition Disorder cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Oxybutynin
University of Alberta
Phase 4BBB
LEVODOPA
Vanderbilt University Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Galantamine Hydrobromide is also rated in:

Alzheimer diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
dementiaDormant
BB
Indicative ·
70 / 100
View asset →
mental disorderDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →